Nanomedicine Vol. 15 No. 7 | Editorial

Nanosponges for combination drug therapy: state-of-the-art and future directions


Combination therapy consists of the co-administration of two or more active molecules to improve a therapeutic response in respect to that of a single drug administration. The rationale of this strategy is to exploit the occurrence of a synergistic effect. Indeed, a drug can affect the activity of another drug, producing a therapeutic benefit [1]. Moreover, co-formulations can improve the patient’s compliance, reducing the number of drug administrations required. The co-delivery of anti-cancer drugs to enhance the therapeutic index and overcome multi-drug resistance in cancer treatment is a paradigmatic example of drug combination [2]. In fact, Vyxeos®, a liposomal combination of daunorubicin and cytarabine contained in the same formulation, is already approved for the treatment of acute myeloid leukemia. Rituxan Hycela® (Mabthera® in Europe) and Herceptin Hylecta® are two anti-cancer marketed products containing co-formulations of antibodies designed to improve their administration.

View the full article Go to Journal Content page